177Lu-DOTA-EB-TATE

N/A

Report date: 2026/02/18 20:02:09
NME

Base Information

Drug Name177Lu-DOTA-EB-TATE
Drug Alias Name177Lu-DOTA-EB-TATEEBTATELutetium-177 DOTA EB TATE
ClassificationRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Nuclides > Lutetium > 177LuRadiation-emitting products > Radionuclide Drug Conjugates +[4
Mechanisms of ActionIonising radiation emitters
TargetsNot applicable
Therapy Area/IndicationsThyroid NeoplasmsNasopharyngeal CarcinomaNeuroendocrine Tumors
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSingaporeMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPending
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsThyroid NeoplasmsNasopharyngeal CarcinomaNeuroendocrine Tumors
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A